Cargando…

Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs

The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Happo, L, Phipson, B, Smyth, G K, Strasser, A, Scott, C L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366076/
https://www.ncbi.nlm.nih.gov/pubmed/22573037
http://dx.doi.org/10.1038/cddis.2012.42
_version_ 1782234709099544576
author Happo, L
Phipson, B
Smyth, G K
Strasser, A
Scott, C L
author_facet Happo, L
Phipson, B
Smyth, G K
Strasser, A
Scott, C L
author_sort Happo, L
collection PubMed
description The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the basis that its deficiency and loss of apoptotic function have been reported in many human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour development, but despite this, we found that Bik deficiency did not accelerate Eμ-Myc-induced lymphomagenesis. Co-operation between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary binding specificities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deficiency of Bik and Noxa did not alter the onset of Eμ-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction of Bik has been reported, neither Eμ-Myc/Bik(−/−) nor Eμ-Myc/Bik(−/−)Noxa(−/−) lymphomas were more resistant than control Eμ-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours.
format Online
Article
Text
id pubmed-3366076
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33660762012-06-04 Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs Happo, L Phipson, B Smyth, G K Strasser, A Scott, C L Cell Death Dis Original Article The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the basis that its deficiency and loss of apoptotic function have been reported in many human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour development, but despite this, we found that Bik deficiency did not accelerate Eμ-Myc-induced lymphomagenesis. Co-operation between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary binding specificities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deficiency of Bik and Noxa did not alter the onset of Eμ-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction of Bik has been reported, neither Eμ-Myc/Bik(−/−) nor Eμ-Myc/Bik(−/−)Noxa(−/−) lymphomas were more resistant than control Eμ-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours. Nature Publishing Group 2012-05 2012-05-10 /pmc/articles/PMC3366076/ /pubmed/22573037 http://dx.doi.org/10.1038/cddis.2012.42 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Happo, L
Phipson, B
Smyth, G K
Strasser, A
Scott, C L
Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
title Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
title_full Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
title_fullStr Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
title_full_unstemmed Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
title_short Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
title_sort neither loss of bik alone, nor combined loss of bik and noxa, accelerate murine lymphoma development or render lymphoma cells resistant to dna damaging drugs
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366076/
https://www.ncbi.nlm.nih.gov/pubmed/22573037
http://dx.doi.org/10.1038/cddis.2012.42
work_keys_str_mv AT happol neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs
AT phipsonb neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs
AT smythgk neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs
AT strassera neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs
AT scottcl neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs